Schizophrenia

RP5063, a dopamine serotonin stabilizer, was associated with symptom improvement in adults with acute exacerbation of schizophrenia or schizoaffective disorder.

A recent meta-analysis estimated years of potential life lost and life expectancy in patients with schizophrenia.

Researchers performed a meta-analysis of data from 18 studies to determine if vitamin and mineral supplementation was effective at reducing psychiatric symptoms in patients with schizophrenia.

When the first episode of psychosis strikes, a rapid response from the medical community is critical.

In a new study, researchers examined the relationship between cannabis use and the risk for developing schizophrenia.